Panel Components:
CD3, CD19, CD34, CD38, CD45, CD79a, CD117, myeloperoxidase

Methodology: FLOW

Clinical Significance:
This two-tube assay is designed to confirm blast lineage in the setting of acute leukemia. These tubes include surface antibodies to CD45, CD34, CD117, CD19, and CD38; one tube contains antibodies to cytoplasmic myeloperoxidase, cytoplasmic CD79a, and cytoplasmic CD3, while the other tube contains isotype controls for the cytoplasmic antibodies.

Organ: Blood/Bone Marrow, Brain/CNS, Lymph Node / Spleen, Thymus (Mediastinal Mass)

Disease State: Acute Myeloid Leukemia (AML) / Myeloid Sarcoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL), Precursor T-Lymphoblastic Lymphoma/Leukemia (T-ALL)

CPT Code(s): 88185x8 (reference only; CPTs may vary)

Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.

Schedule: Monday-Saturday

Specimen Requirements:
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Tissue: Finely minced tissue in RPMI transport media - OR -
• Body fluids: In RPMI transport media